← 홈

ADC · HER2+ 유방암

281개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 281개
ADCBiologicstaleByondis B.V.Phase 3

trastuzumab (Herceptin, vic-, (vic-)trastuzumab duocarmazine)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1
효능 ORR 27.8%임상시험 23상태 ACTIVE
ADCBiologicstaleRochePhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, HER2,trastuzumab deruxtecan± pertuzumab)

Salivary Gland Carcinoma; Precision Therapy · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 1%임상시험 23상태 RECRUITING
ADCBiologicstaleShanghai Henlius BiotechPhase 3

TCbHP (TCbHP)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 23상태 RECRUITING
ADCBiologicstaleInstitut du Cancer de Montpelli…Phase 1

TDM1 (TDM1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 9.3%임상시험 22상태 ACTIVE
ADCBiologicstaleRisen (Suzhou) Pharma Tech Co.,…Preclinical

Pyrotinib Maleate Tablets (Pyrotinib Maleate Tablets)

HER2+ Advanced Breast Cancer Patients Progressing on TKI Therapy · HER2

#HER2#ADC#Preclinical#항체약물접합체#antibody-drug-conjugate+2
임상시험 20상태 ACTIVE
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Ribociclib with ET (Ribociclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
임상시험 20상태 DISCONTINUED
ADCBiologicstaleSichuan Baili Pharmaceutical Co…Phase 3

BL-M07D1 (BL-M07D1)

HER2-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 18상태 RECRUITING
ADCBiologicstaleFondazione per la Medicina Pers…Phase 3

Pralsetinib (Pralsetinib)

Breast Cancer; Gastrointestinal Cancer · Solid Tumor

#SolidTumor#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 53.8%임상시험 18상태 ACTIVE
ADCBiologicstaleMabwell (Shanghai) Bioscience C…Phase 3

9MW2821 (9MW2821)

Locally Advanced or Metastatic Triple-negative Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 RECRUITING
ADCBiologicstaleDanish Breast Cancer Cooperativ…Phase 3

Abemaciclib with ET (Abemaciclib with ET)

Metastatic Breast Cancer; ER-positive Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 0%임상시험 17상태 DISCONTINUED
ADCBiologicstaleRemeGenPhase 2

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin Tislelizumab)

Her2 Overexpressing High-Risk Non-Muscle Invasive Bladder Urothelial Carcinoma · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleRemeGenApproved

disitamab vedotin (Disitamab Vedotin, RC48, Disitamab Vedotin combined with Tislelizumab)

Breast Cancer; Neoadjuvant Therapy · Breast Cancer

#BreastCancer#ADC#Approved#항체약물접합체#antibody-drug-conjugate+2
임상시험 17상태 ACTIVE
ADCBiologicstaleGenentech, Inc.Phase 1

GDC-0941 (GDC-0941)

Metastatic Breast Cancer · Metastatic Breast Cancer

#MetastaticBreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+1
임상시험 17상태 ACTIVE
ADCBiologicstaleShanghai JMT-Bio Inc.Phase 2

KN026 (KN026)

HER2-positive Colorectal Cancer; HER2-positive Biliary Tract Cancer · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleSuzhou Suncadia Biopharmaceutic…Phase 2

SHR-A1921 (SHR-A1921)

Advanced Breast Cancer; Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+3
임상시험 17상태 RECRUITING
ADCBiologicstaleDaiichi SankyoPhase 3

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, T-Dxd + Pertuzumab)

HER2 + Breast Cancer · HER2

#HER2#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+2
효능 ORR 1%임상시험 17상태 RECRUITING
ADCBiologicstaleQuantumLeap Healthcare Collabor…Phase 1

ALX148 (ALX148)

HER2-positive Breast Cancer; Metastatic Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
임상시험 15상태 RECRUITING
ADCBiologicstaleAstraZenecaPhase 2

AZD5305 (AZD5305)

Ovarian Cancer; Breast Cancer · Ovarian Cancer

#OvarianCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleShanghai Junshi Bioscience Co.,…Phase 2

JS207 (JS207)

Non-squamous Non-small Cell Lung Cancer · HER2

#HER2#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+2
임상시험 15상태 RECRUITING
ADCBiologicstaleCelgenePhase 1

Valemetostat (Valemetostat)

Aggressive Variant Prostate Carcinoma; Castration-Resistant Prostate Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3
효능 ORR 43.7%임상시험 15상태 RECRUITING

7 / 15 페이지

← 이전다음 →